Lenacapavir approved in the US for multidrug resistant HIV
Simon Collins, HIV i-Base
On 22 December, the US FDA approved the capsid inhibitor lenacapavir for multidrug resistant HIV. 
Lenacapavir is a long-acting drug given by subcutaneous injection.
It was approved in the EU by the EMA in August 2022, 
- Gilead press release Sunlenca (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. (22 December 2022).
- Lenacapavir approved in the EU and UK to treat multidrug resistant HIV. HTB September 2022.
This report was first posted online in December 2022.